This molecule binds the TK ATP binding pocket, with a high binding specificity in a conserved cysteine (Cys) residue [19], leading to cell death, by a ferroptosis mechanism [20,21], with woman breast cancer patients having the acquired mutation at the residue T798I in HER2 and/or HER4 overexpression showing neratinib resistance [22]. The gene discussed is ERBB2; the disease is breast cancer.